YL201 received another Breakthrough Therapy Designation for the treatment of R/M Nasopharyngeal Carcinoma

CAR-T Digest - August 2020

20 Jan 2025: YL201 received another Breakthrough Therapy Designation for the treatment of R/M Nasopharyngeal Carcinoma

MediLink receives CDE Breakthrough Therapy Designation for YL201 for recurrent/metastatic nasopharyngeal carcinoma following prior designation for SCLC
YL201 targets B7-H3, offering a promising therapeutic approach with minimal normal tissue expression
YL201 is developed using MediLink’s TMALIN® platform, being tested in global clinical trials for multiple solid tumors
Two pivotal trials are ongoing in China for R/M NPC and SCLC, with additional combination studies for earlier treatment lines